Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/17/2026, 12:00:00 AM
HSBC downgraded the stock to "Reduce" from "Hold," citing concerns that the obesity drug market is overvalued. The stock fell approximately 6% on the day of the announcement.
Korean Translation
HSBC가 비만 치료제 시장이 고평가되었다는 우려를 제기하며 투자의견을 '보유'에서 '축소'로 하향 조정함. 발표 당일 주가는 약 6% 하락함.
Related Recent Events
Lululemon Athletica Inc (LULU) · Earnings Release
Q1 2026 earnings release scheduled. This is an estimated date based on past reporting schedules.
5/28/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled; a price impact of at least 1% is expected.
4/30/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Q1 2026 earnings release with adjusted EPS guidance of $1.12 to $1.18, for which a ≥1% price impact is estimated, scheduled.
4/15/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Other
Quarterly dividend ex-date of $0.63 per share on 2026-04-15, for which a ≥1% price impact is estimated, scheduled.
4/15/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
New target action date for the FDA's decision on oral obesity drug orforglipron, following an extension of the review period announced on January 15, 2026, scheduled; a price impact of at least 1% is expected.
4/10/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Quarterly dividend of $1.25 per share, a 3% increase, will have its ex-dividend date on March 27, 2026. The dividend is payable on April 10, 2026. A 1% price impact is estimated due to the dividend increase, scheduled.
3/27/2026, 12:00:00 AM